Will the widespread adoption of gene-editing technologies like CRISPR lead to a new era of eugenics and social inequality?

Opening Statement

Affirmative Opening Statement

This is not science fiction. This is not speculation. This is the quiet beginning of a new biological order—one where your child’s future is no longer shaped by chance, but by credit score.

We affirm the motion: The widespread adoption of gene-editing technologies like CRISPR will lead to a new era of eugenics and social inequality. And make no mistake—this is not the crude, state-mandated eugenics of the past. It is subtler, more insidious, and far more dangerous because it wears the mask of choice, progress, and medicine.

Let us define our terms clearly. By widespread adoption, we mean the normalization of germline editing beyond rare disease correction into enhancement and trait selection. By eugenics, we do not mean only forced sterilizations—but any systematic effort to shape the genetic makeup of future generations, whether through policy or market pressure. And by social inequality, we mean a deepening divide not just in wealth, but in biological potential.

Our case rests on three pillars.

First: Therapeutic intent is a slippery slope to consumer enhancement.
Today, CRISPR is celebrated for curing sickle cell anemia. Tomorrow, it will be used to boost IQ, immunity, and appearance. The boundary is already blurring. In vitro fertilization clinics already offer embryo screening for intelligence-linked genes. Once editing enters the picture, parents won’t ask, “Can we prevent suffering?”—they’ll ask, “Can we give our child an edge?” And when one parent edits, social pressure forces all to follow. What begins as healing becomes arms racing—in genes.

Second: Access will be determined by wealth, not need.
Gene therapies cost millions today. Insurance covers them unevenly. Will we really believe that CRISPR enhancements will be distributed fairly? No. The rich will buy resilience, longevity, and brilliance—while the poor inherit unedited risk. Within decades, we may see a genetic caste system: a cognitively enhanced elite who dominate finance, politics, and science, not by merit, but by design. This isn’t inequality—it’s biological stratification. And once encoded in DNA, it self-replicates across generations.

Third: Social norms will normalize coercion disguised as choice.
Imagine a job market where 80% of applicants are genetically optimized. Is it still a “choice” not to edit your child? When schools track edited vs. unedited students, when dating apps filter by genetic profiles, when insurers charge more for “high-risk” genomes—freedom evaporates. This is soft eugenics: not commanded by the state, but demanded by society. Like cosmetic surgery today, it starts optional, ends expected.

We are not anti-science. We are pro-caution. Because once we open the door to editing human embryos for non-essential traits, we cannot close it. The logic of improvement has no natural stopping point. And history warns us: every eugenic movement began with good intentions.

The question is not whether we can edit genes. It is whether we should unleash a technology that could make inequality permanent—written not in law, but in life itself.

Negative Opening Statement

Ladies and gentlemen, let me begin with a question: If we could eliminate cystic fibrosis with a single edit, would we refuse—because we fear someone, somewhere, might misuse the same tool to select eye color?

We reject the motion: The widespread adoption of gene-editing technologies like CRISPR will not lead to a new era of eugenics and social inequality. Not because we ignore risks—but because we recognize that fear must not override compassion, progress, or justice.

Let us be clear: eugenics was a crime against humanity—a state-enforced program of exclusion and violence. To equate that horror with parents using safe, regulated medicine to protect their children is not just inaccurate. It is offensive.

CRISPR is not a weapon of oppression. It is a scalpel of hope. And our response should not be retreat—but responsibility.

Our case stands on three foundations.

First: Regulation and ethics can—and already do—contain misuse.
The world is not asleep. Over 70 countries have binding laws on germline editing. The WHO, UNESCO, and national bioethics boards have drawn red lines: no enhancement, no heritable edits without oversight. Scientists themselves halted after He Jiankui’s rogue experiment. This is not the Wild West—it is one of the most scrutinized fields in science. To claim we are helpless is to deny human capacity for governance.

Second: Gene editing democratizes health, not inequality.
Yes, early treatments are expensive. So were pacemakers. So was the internet. But costs fall. CRISPR-based therapies are becoming cheaper than chronic care. Sickle cell treatment now costs $2 million—but mass production could bring it below $10,000. Public health systems in the UK, Canada, and South Korea are already planning subsidized access. The real injustice would be to deny the poor these cures out of abstract fear of hypothetical futures.

Third: Individual autonomy is not eugenics—it is liberation.
Eugenics stripped people of choice. Gene editing restores it. For parents carrying Huntington’s disease, CRISPR offers a way to break generational chains of suffering. For families facing miscarriages due to chromosomal issues, it brings dignity. This is not coercion—it is consent. And when people choose to reduce disease risk, they are not creating a master race. They are exercising reproductive freedom—long fought for, now expanding with science.

Let us also challenge the dystopian imagination. The idea that we’ll have “genetic castes” assumes editing is easy, precise, and predictable. But most traits—intelligence, personality, creativity—are influenced by thousands of genes and environmental factors. You cannot “design” a genius. What we can do is prevent agony.

The true danger isn’t progress. It’s paranoia. If we ban or stigmatize gene editing, we don’t prevent inequality—we guarantee it. Because then only the rich will go offshore to get what the rest of us are denied.

We stand not for reckless ambition, but for compassionate innovation. Not for a new eugenics—but for a new era of healing.

Rebuttal of Opening Statement

Affirmative Second Debater Rebuttal

Let me begin by thanking my opponents for their eloquent defense of progress—but let us not confuse hope with reality.

They stand before you and say: Regulation will save us. Seventy countries have laws! Ethics boards draw red lines! Scientists policed themselves after He Jiankui!

Forgive me if I’m not comforted.

Yes, there are rules on paper. But tell me—where were those rules when a Chinese scientist edited twin girls in secret? Where are they now, when fertility clinics in Mexico, Dubai, and Tijuana offer unregulated embryo selection under the guise of “reproductive freedom”? Regulation exists—but so does regulatory arbitrage. And the wealthy don’t wait for permission. They buy it elsewhere.

You cannot govern technology at the speed of bureaucracy when the market moves at the speed of venture capital.

Next, they claim: Costs will fall. Access will democratize. This is no different than pacemakers or the internet.

But gene editing is not a smartphone. It is not even a vaccine. It is a heritable intervention—one that alters not just an individual, but potentially an entire lineage. And history shows us that falling prices do not guarantee equity. Look at IVF: invented nearly 50 years ago, still inaccessible to most of the world. In the U.S., one cycle costs $12,000—with no insurance coverage in half the states. If we can’t make fertilization fair, how will we make genetic optimization just?

And then comes their most seductive argument: This is liberation. Parents choosing health for their children—that’s reproductive freedom.

But let’s be honest: when did “freedom” become mandatory?

If every parent edits for immunity, intelligence, or height, then the unedited child isn’t free—they’re disadvantaged. When schools track cognitive performance by genetic profile, when colleges ask for genome reports alongside transcripts, when dating apps show your polygenic risk score—what choice remains?

This isn’t eugenics by decree. It’s eugenics by default.

And don’t let them fool you with false modesty about complexity. Yes, intelligence involves thousands of genes. But CRISPR doesn’t need perfection to create advantage. Even a 5-point IQ boost, combined with better memory or faster neural processing, can open doors. And in a winner-take-all economy, small edges compound across generations.

They say we fear hypothetical futures. But redlining was once hypothetical. Apartheid was once theoretical. So was the atomic bomb.

Progress without guardrails isn’t progress—it’s acceleration toward a cliff.

We agree: curing disease is noble. But noble intent doesn’t immunize us from consequence. The road to biological caste systems isn’t paved with malice. It’s paved with upgrades.

Negative Second Debater Rebuttal

My friends on the affirmative paint a haunting picture—a world split between the genetically rich and poor, parents coerced by invisible social forces, science spiraling into designer babies.

It’s a compelling narrative. Almost cinematic.

But it rests on three dangerous assumptions: that regulation fails by default, that enhancement is inevitable, and that personal choice is indistinguishable from societal coercion.

Let’s dismantle them—one by one.

First, they argue that regulation is toothless because of rogue actors like He Jiankui. But one criminal does not invalidate an entire system. We don’t ban cars because some drive drunk. We strengthen traffic laws. After He’s experiment, China sentenced him to prison, the WHO fast-tracked global governance frameworks, and scientists worldwide called for moratoria. This isn’t failure—it’s feedback. To claim we are powerless is to ignore the very institutions designed to protect us.

Second, they assume therapy inevitably slides into enhancement. But this slippery slope is neither smooth nor unavoidable. There is a categorical difference between preventing cystic fibrosis and selecting for musical talent. Medicine has always drawn such lines—between treatment and doping, surgery and augmentation. We regulate steroids. We restrict cosmetic procedures for minors. We can—and will—do the same here.

And let’s talk about what enhancement actually requires. The affirmative dreams of IQ-boosting edits. But intelligence isn’t coded in a single gene. It’s shaped by over 10,000 variants, epigenetics, environment, nutrition, education. You can’t CRISPR genius any more than you can edit someone into being Mozart with a piano app. The science itself resists their dystopia.

Finally, they reframe parental choice as coercion. “If others edit, won’t I have to?” they ask. But since when does social competition equal oppression?

People take SAT prep courses. They hire tutors. They move to better school districts. None of that turns education into eugenics. Why? Because improving opportunity through effort—or yes, even expense—is not inherently unjust. It only becomes unjust if we refuse to expand access for all.

Their vision assumes a zero-sum world where one child’s gain is another’s loss. Ours believes in rising tides. Instead of banning boats, we build more.

And let’s not forget: the greatest victims of inaction are those suffering today. A child with spinal muscular atrophy doesn’t care about philosophical debates. They care about breathing.

To deny them life-saving tools because someone, somewhere, might misuse the technology—that isn’t caution. That’s cruelty masked as ethics.

We do not dismiss concerns about inequality. But we reject fatalism. With public investment, global cooperation, and tiered pricing models—like those used for HIV drugs—we can ensure CRISPR reaches the many, not just the few.

Eugenics sought to eliminate. Gene editing seeks to heal.

One strips dignity. The other restores it.

Let us not punish the future for the sins of the past.

Cross-Examination

In the crucible of debate, no moment tests rigor like cross-examination. Here, logic is stripped bare. Assumptions are probed. Contradictions exposed. The third debaters step forward not to explain, but to interrogate—to turn the opposition’s words into traps, and their own coherence into armor.

The affirmative begins, aiming to dismantle the negative’s faith in regulation and choice. The negative counters, seeking to reframe fear as irrational obstruction. What follows is not mere Q&A—it is philosophical combat.

Affirmative Cross-Examination

Affirmative Third Debater:
To the first debater of the negative side: You claim that current regulations prevent a slide into enhancement. But your own opening cited He Jiankui as proof that scientists can self-correct. Isn’t the very fact that he succeeded—editing human embryos in secret—a demonstration that oversight is porous, not protective?

Negative First Debater:
It is a demonstration that violations occur—but also that they are met with global condemnation and legal consequences. One breach does not invalidate a system; it reveals the need for stronger enforcement.

Affirmative Third Debater:
Then to the second debater: You argued that intelligence cannot be edited because it involves thousands of genes. But if parents can select embryos with a 5% higher polygenic score for education attainment—and do so generation after generation—isn’t that cumulative advantage indistinguishable from engineered superiority?

Negative Second Debater:
Statistical tendency is not deterministic design. Choosing from existing variation is not the same as editing for enhancement. And environment remains decisive.

Affirmative Third Debater:
Finally, to the fourth debater—though they have yet to speak: You believe gene editing restores autonomy. But when insurance companies begin charging higher premiums for unedited genomes, or employers favor candidates with lower Alzheimer’s risk scores, will parental “choice” not become economic compulsion? Is that freedom—or market-enforced eugenics?

Negative Fourth Debater:
Those are speculative abuses of data, not inherent outcomes of gene editing. We regulate insurers. We ban genetic discrimination. To punish a life-saving technology for potential misuses elsewhere is to confuse cause with context.

Affirmative Cross-Examination Summary

Ladies and gentlemen, what did we just hear?

We heard admission: yes, rogue actors can edit babies today. Oversight failed once—what stops it from failing again, especially where profit beckons?

We heard dismissal: “polygenic scores don’t guarantee genius.” True. But evolution doesn’t require perfection—only incremental advantage. A 5% cognitive edge, compounded over generations, reshapes lineages. That is not science fiction. It is statistics.

And we heard evasion: “discrimination is illegal.” Wonderful—on paper. So was redlining. So were Jim Crow laws. Laws do not erase power; they reflect it. When biology becomes branded, and genomes become resumes, no anti-discrimination statute can undo the silent stigma of being naturally born.

They say this isn’t eugenics. But when society rewards one genome and penalizes another, the mechanism matters less than the outcome.

Choice? Only if you can afford the upgrade.

Negative Cross-Examination

Negative Third Debater:
To the first debater of the affirmative: You warn of a genetic caste system. But if CRISPR therapies for sickle cell disease become universally covered by public health systems—as they are being piloted in the UK and Canada—doesn’t that suggest a path toward equity, not inequality?

Affirmative First Debater:
Pilot programs exist, yes. But universal coverage is the exception, not the rule. In the U.S., rare disease treatments often exceed $1 million—with minimal insurance support. Hope is not policy.

Negative Third Debater:
To the second debater: You claimed that choosing health is a slippery slope to enhancement. But we already distinguish medical treatment from cosmetic surgery. Why can’t we draw the same line here—say, allowing edits for Tay-Sachs but not for height?

Affirmative Second Debater:
Because the line blurs the moment enhancement offers survival advantage. Is immunity to pandemics therapy? What about neural processing speed in a digital economy? Once the benefit is framed as health-adjacent, the gate swings open.

Negative Third Debater:
Finally, to the fourth debater—who may yet surprise us: You argue that social pressure turns choice into coercion. But parents already invest unequally in tutoring, nutrition, and private schools. Does that make education a eugenic project? Or does it simply reflect the reality of parental love in an unequal world?

Affirmative Fourth Debater:
Investment in environment is reversible, redistributable, and subject to public policy. Genetic edits are permanent, heritable, and biologically embedded. One shapes opportunity. The other reshapes human inheritance.

Negative Cross-Examination Summary

Let us be clear about what has just unfolded.

First: the affirmative concedes that equitable access is possible—they merely doubt it. But skepticism is not argument. If we reject every innovation until perfection is guaranteed, we would still be living in caves, fearing fire.

Second: they admit we can distinguish therapy from enhancement—but insist the line will be crossed. Yet medicine draws such boundaries daily. We allow vaccines; we ban steroids in sports. Complexity does not excuse surrender.

And third: they elevate genetic intervention above all other forms of advantage—while ignoring that society already tolerates vast disparities in upbringing, wealth, and education. If hiring a $300-an-hour tutor isn’t coercion, why is preventing childhood blindness?

Their entire case rests on a double standard: environmental privilege is acceptable inequality; biological improvement is unforgivable eugenics.

But let us not forget who loses in their vision: the child born with a fatal monogenic disorder, whose cure is delayed because we fear someone, somewhere, might want a taller child.

Compassion is not eugenics. Prevention is not oppression. And caution without action is just another form of abandonment.

Free Debate

Affirmative First Debater:
You say regulation works because He Jiankui was punished. But tell me—when a bank robs a vault and returns half the money, do we call it a functioning financial system? One rogue scientist doesn’t break the rules—he exposes them. And right now, fertility clinics in Tijuana are selling “genetic optimization” packages with CRISPR add-ons. The black market isn’t coming. It’s already here.

Negative First Debater:
And yet, no country has legalized germline editing for enhancement. The scientific consensus holds. We’re not handing out Nobel Prizes to biohackers—we’re prosecuting them. If your entire case rests on unregulated clinics in border towns, then your dystopia is less about CRISPR and more about global inequality itself. Don’t blame the scalpel for the surgeon’s greed.

Affirmative Second Debater:
Ah yes, let’s just fix global inequality—over brunch! But until then, every dollar spent on embryo selection is a vote against public health. When parents can buy immunity to Alzheimer’s for their kids, guess what happens to nursing homes? They become poor people’s prisons. Biology becomes destiny again—this time written in venture capital ink.

Negative Second Debater:
So prevention is oppression now? Because someone avoids disease, others must suffer it? That’s not equity—that’s envy dressed up as ethics. We don’t ban vaccines because not everyone has access. We expand access. CRISPR could end sickle cell anemia globally. Are you really saying we should wait until every village has a lab before curing anyone?

Affirmative Third Debater:
No one opposes curing disease. But where does therapy end and enhancement begin? Is resistance to depression therapy? What about higher pain tolerance? In Silicon Valley, they already call burnout “a feature.” If you edit kids to thrive in toxic workplaces, are you healing—or weaponizing biology?

Negative Third Debater:
Then draw the line clearly. Ban non-medical edits. Regulate polygenic screening. Create genetic anti-trust laws. But don’t throw the cure out with the pipette water. Your logic implies we must freeze progress until perfection arrives. By that standard, fire was too risky—someone might’ve burned down a cave.

Affirmative Fourth Debater:
Perfection isn’t the standard—power is. You talk about drawing lines, but markets erase them. Once insurance companies see genome reports, they’ll charge premiums based on mutation risk. “Voluntary” choice becomes economic survival. Soon, being born unedited isn’t natural—it’s negligent parenting.

Negative Fourth Debater:
And yet, GINA—the Genetic Information Nondiscrimination Act—already bans that in the U.S. Laws exist. Enforcement can improve. But to say we shouldn’t develop cures because bad actors might misuse data is like banning literacy because someone wrote a hate speech.

Affirmative First Debater:
GINA doesn’t apply to life insurance. Or long-term care. Or employers with fewer than 15 employees. It’s full of loopholes wider than a plasmid. And even if it didn’t—stigma doesn’t need legality. Imagine your child’s school sharing cognitive potential scores from prenatal scans. No law stops whispers. No statute silences silence when everyone knows yours wasn’t “optimized.”

Negative First Debater:
So now schools are running DNA analytics labs during recess? Let’s ground this in reality. Parents already invest unequally—in tutors, nutrition, enrichment camps. You don’t call that eugenics. Why is changing DNA different? Because it’s permanent? Then let’s regulate permanence—not punish potential.

Affirmative Second Debater:
Because environmental advantages don’t replicate across generations like genetic edits do. Tutoring ends when the kid graduates. A germline edit echoes forever. You’re not just upgrading one life—you’re rewriting a bloodline. That’s not parenting. That’s species engineering on installment plans.

Negative Second Debater:
And nature does it freely—through inheritance. Wealthy families pass down advantages biologically and financially. CRISPR might actually level that playing field. Imagine a low-income child edited to avoid hereditary cancer. Is that injustice? Or the first fair shot she ever had?

Affirmative Third Debater:
Fair only if available to all. But these treatments cost millions today. Vertex’s gene therapy for sickle cell is $2.2 million per patient. You think that’s going to trickle down like cryptocurrency? Please. The only thing spreading faster than CRISPR is the myth of democratization.

Negative Third Debater:
Costs fall. Insulin was once scarce. So was IVF. Universal coverage models are emerging. Canada funds CAR-T therapy. The UK’s NHS is negotiating CRISPR pricing. You keep citing current inequity as proof of inevitable caste systems—as if society can’t learn, adapt, or legislate better.

Affirmative Fourth Debater:
We learned after thalidomide. We adapted after Tuskegee. And still, harm outran reform. Why assume this time is different? Because scientists mean well? Good intentions built the old eugenics movement too. They called it “scientific charity.” Now we call it genocide.

Negative Fourth Debater:
What a stretch. Preventing spinal muscular atrophy is not exterminating populations. You equate compassion with coercion, progress with persecution. If that’s your worldview, then yes—every cure looks suspicious. But most of us see hope where you only smell hubris.

Affirmative First Debater:
Hope without guardrails is just another name for acceleration. We’re not against CRISPR—we’re against naïveté. The question isn’t whether we can edit genes, but who decides which edits matter. When intelligence, appearance, and resilience become commodities, evolution goes retail. And retail always has a loyalty program—for the rich.

Negative First Debater:
Then fight for universal access. Subsidize treatments. Mandate public funding. But don’t ban the tool because the world isn’t yet just. That’s like refusing to invent antibiotics because some hospitals lack clean water. Justice requires medicine—not its denial.

Affirmative Second Debater:
Justice also requires humility. We barely understand gene networks. Epigenetics shows environment switches genes on and off. Edit one trait, destabilize ten others. The first CRISPR babies may be infertile—we don’t know. Playing God without a manual isn’t courage. It’s corporate-sponsored roulette.

Negative Second Debater:
Which is why we test. We trial. We regulate. Unlike natural conception—which comes with zero safety checks and a 1-in-75 chance of major birth defects—we proceed cautiously. At least with CRISPR, we aim. Nature? Nature throws darts blindfolded.

Affirmative Third Debater:
And yet, you’d trust those same regulators who missed He Jiankui to oversee global enhancement pipelines? The fox isn’t just guarding the henhouse—you’re offering it a key to the genetics lab.

Negative Third Debater:
Then build a better lock. Not a prison for science. The alternative isn’t purity—it’s paralysis. While we debate, children die. Parents grieve. Families collapse under rare disease burdens. Your caution sounds noble—until you meet a mother watching her son forget how to breathe.

Affirmative Fourth Debater:
And your urgency sounds heroic—until you realize her son’s cure could become the blueprint for a subclass of unedited humans deemed “naturally defective.” Compassion today must not create cruelty tomorrow. Otherwise, we heal one wound by opening a civilizational one.

Negative Fourth Debater:
Then let’s heal and protect. Regulate fiercely. Invest broadly. Educate widely. But let’s not romanticize the status quo—a world where genetics already determine fate through inherited wealth, disease, and opportunity. CRISPR isn’t creating inequality. It might finally challenge it.

Closing Statement

The final word in any debate is not just a summary—it is a verdict in advance. It asks the audience not only to recall what was said, but to feel its weight, to see the stakes beyond logic trees and policy papers. In this moment, both teams step back from the battlefield of facts to gaze at the horizon: one sees a warning flare, the other a dawn. Let us hear them now—not as debaters, but as witnesses to a future still unwritten.

Affirmative Closing Statement

We Are Not Against Science—We Are Against Naïveté

From the beginning, our case has never been that CRISPR is evil. It is that power without equity is peril. That progress without guardrails becomes predation. And that when biology becomes editable, inequality becomes inheritable.

We have shown, consistently and across every stage of this debate, that the slide from therapy to enhancement is not speculative—it is already underway. Polygenic risk scores are being used today in IVF clinics to select embryos with higher probabilities of educational attainment. Is that healing? Or is it the first whisper of a new biological aristocracy?

You heard the Negative side say: “Regulation will stop abuse.” But He Jiankui edited babies—and all he lost was his job. Meanwhile, clinics in Dubai and Tijuana advertise “genetic optimization” like boutique wellness packages. The black market isn’t waiting for permission. It’s already selling upgrades.

They say costs will fall—like insulin, like IVF. But insulin still kills people who can’t afford it. IVF remains a luxury for the few. And Vertex’s CRISPR therapy for sickle cell disease costs $2.2 million. Tell me: when did trickle-down genetics ever work?

Worse still, they dismiss social pressure as irrelevant. But when insurance companies deny coverage based on unedited genomes, when schools track cognitive potential from prenatal scans, when “natural birth” becomes synonymous with negligence—choice vanishes. What remains is soft eugenics: not state mandates, but market forces and whispered shame rewriting evolution one premium payment at a time.

And let us be clear: germline edits do not end with one generation. They echo through bloodlines. Unlike tutoring or nutrition, these advantages compound biologically. This isn’t parenting. It’s species engineering on credit—with interest paid by those left unmodified.

Do not mistake our caution for cruelty. We too want to end suffering. But we refuse to accept a world where healing some creates a permanent underclass of the “naturally born.” Eugenics did not begin with gas chambers. It began with good intentions, scientific confidence, and the quiet belief that some lives were more worth inheriting than others.

We stand not against CRISPR—but against the fantasy that technology alone can redeem society. If we do not act now to mandate equitable access, ban heritable enhancements, and protect genetic privacy, then yes: we are ushering in a new era of eugenics. Not by design. By default.

The question is not whether we can edit genes.
It is: who decides which traits matter?
And whose children get left behind?

Vote for restraint. Vote for justice. Vote for a future where dignity is not determined by DNA.

Negative Closing Statement

Compassion Is Not Coercion—And Progress Is Not a Crime

Let us cut through the dystopian noise.

At the heart of this debate lies a child—a real child—born with spinal muscular atrophy, unable to breathe without machines. Another with Tay-Sachs, destined to lose every ability before age five. Another with sickle cell disease, enduring pain so severe hospitals call it “vaso-occlusive crisis”—a clinical term for agony.

CRISPR offers them hope. Real, tangible, life-saving hope.

And what does the Affirmative say? “Wait.” Wait until the world is perfectly equal. Wait until every clinic is free. Wait until no parent dares dream of giving their child an advantage.

But while we wait, children die. Families break. Generations suffer from diseases we could prevent.

Yes, regulation matters. Yes, equity matters. But to halt progress because misuse might happen somewhere, someday, is not wisdom—it is surrender dressed as ethics.

They invoke eugenics—as if preventing childhood blindness is equivalent to forced sterilization. Let us be morally precise: eugenics was state violence. It was coercion. It was elimination. What we are discussing today is parental love—parents using safe, precise tools to spare their children suffering.

And yes, we can draw lines. We ban performance-enhancing drugs in sports. We regulate plastic surgery. We distinguish medical necessity from cosmetic desire. Medicine does this every day. Why can’t we trust ourselves to do it here?

They fear a genetic caste system. But look at the pilot programs in the UK and Canada—public systems funding CRISPR therapies. Look at scientists advocating tiered pricing, global access compacts, open-source protocols. The arc of medical history bends toward democratization—not monopoly.

Insulin was once rare. So was penicillin. So was HIV treatment. And yet, through public pressure, innovation, and investment, they became accessible. CRISPR can follow the same path—if we let it begin.

The Affirmative treats all advantage as contamination. Tutoring? Fine. Private schools? Acceptable. But changing DNA to prevent cancer? That’s dangerous. That’s eugenic.

Why? Because biology feels more permanent? Then regulate permanence. Don’t punish potential.

We do not live in a perfect world. But justice does not require stagnation. It requires expansion. It requires that we fight for universal access—not reject cures because not everyone has them yet.

Imagine a future where no child dies of Huntington’s. Where cystic fibrosis is eradicated. Where a low-income family can finally break the chain of inherited disease—not through luck, but through science.

That is not eugenics.
That is liberation.

Do not romanticize the status quo, where genetics already determine fate through wealth, illness, and premature death. CRISPR doesn’t create inequality. For the first time in history, it gives us a chance to challenge it.

So let us move forward—not blindly, but bravely. With rules. With care. With conscience.

But let us move.

Because the alternative is not caution.
It is complicity in preventable suffering.

Vote for healing. Vote for inclusion. Vote for a future where every child, regardless of birth, gets a fair shot at life.